Avaliação do impacto da terapia tripla para Hepatite C sobre a qualidade de vida relacionada à saúde de pacientes cronicamente infectados

• Ano de defesa: 2016
• Autor(a) principal: Souza, Samara Ercolin de [UNIFESP]
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de São Paulo (UNIFESP)
• Palavras-chave em Português: Quality of life; Hepatitis c; Treatment; Qualidade de vida; Hepatite c; Tratamento
• Link de acesso: https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=3798151; http://repositorio.unifesp.br/handle/11600/47655

ims: To evaluate the impact of triple therapy with Boceprevir and Telaprevir on the health-related quality of life (HRQOL) of patients chronically infected with hepatitis C. To compare the HRQOL of the patients before treatment with the HRQOL of different moments during the therapy. To associate HRQOL with epidemiological, clinical and histological variables. Methods: Descriptive, observational longitudinal study conducted in Hepatitis Sector of Gastroenterology Discipline of the Universidade Federal São Paulo. Coinfected with HIV and HBV were excluded. A standard questionnaire was applied to investigate sociodemographic, clinical and histological aspects. Survey forms to assess of HRQOL - Short Form 36 (SF-36), Liver Disease Quality of life (LDQOL) - were applied in four moments: pre-treatment, 1º month, 3º month and 6º month of therapy. In the comparative analysis the relation between HRQOL and clinical and therapeutic variables was evaluated. Results: 38 patients were included, the majority of women (55%) with a mean age of 52±10 years. Most part was cirrhotic (61%), in retreatment (66%) and used telaprevir (61%). During the course of therapy 16 patients discontinued treatment, most due to adverse events. Pre-treatment moment had the highest HRQOL average. The 3º month of treatment showed the lowest average quality of life related to health. For the SF-36 the differences were in the domains: physical limitation, functioning, pain, vitality, social and mental health aspects. In accord with LDQOL, the differences were in the domains: symptoms of liver disease, effects of liver disease, concentration and sleep. The domain hope presented the highest score over all moments of the study; on the other hand the domains with lower scores, which had stayed low during the hole treatment were related to sexual sphere. In the comparative analysis men had lower HRQOL scores, as well as patients with less than 52 years, with higher education, naives and not submitted to lead-in.